MPR Weekly Dose Podcast
This week we cover the latest COVID-19 developments including a triple antiviral therapy that looks promising, Emergency Use Authorizations granted to diagnostics and critical meds, Moderna’s investigational vaccine gets Fast Tracked, and the National Institute of Health’s remdesivir plus baricitinib trial.
Drugs in the Pipeline, Uncategorized
Lilly and Incyte announced positive top-line results from two Phase 3 clinical trials evaluating baricitinib for the treatment of adult patients with moderate to severe atopic dermatitis. Results from the BREEZE-AD1 and BREEZE-AD2 placebo-controlled trials showed that treatment with baricitinib monotherapy led to a statistically significant proportion of patients achieving Investigator’s Global Assessment for Atopic Dermatitis score of clear…
The panel's decision was based on four Phase 3 studies which evaluated the impact of baricitinib on RA signs and symptoms, physical function, joint damage progression and other patient-reported outcomes.